Dr. Ferris Discusses the RTOG 3504 Study in Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Tuesday, Jun 13, 2017



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.

This was a randomized phase II study of chemoradiation with or without nivolumab (Opdivo) with sequential safety evaluations of nivolumab with or without lirilumab or ipilimumab (Yervoy) concomitant with chemoradiation in intermediate- and high-risk head and neck squamous cell carcinoma.

Ferris says that the trial aims to look at an intensification of the standard-of-care by adding immunotherapy.


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.

This was a randomized phase II study of chemoradiation with or without nivolumab (Opdivo) with sequential safety evaluations of nivolumab with or without lirilumab or ipilimumab (Yervoy) concomitant with chemoradiation in intermediate- and high-risk head and neck squamous cell carcinoma.

Ferris says that the trial aims to look at an intensification of the standard-of-care by adding immunotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x